In the activation of HPV-specific human B cells HPV-VLP vaccines mimic membrane-associated antigens

C Charles Torgbor (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) H Haewon Sohn (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) B Brian L. P. Dizon (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) E Evan C. Mutic (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) R Rachel George (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) K Kihyuck Kwak (Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine) M Munir Akkaya (Division of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, The Ohio State University) E Esin Bayrali Ulker (Division of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, The Ohio State University) M Maria Traver (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) J Joseph Brzostowski (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH) D Denise A. Galloway (Human Biology Division, Fred Hutchinson Cancer Research Center) C Cynthia D. Thompson (Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH) N Nicolas Çuburu (Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH) J John T. Schiller (Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH) S Susan K. Pierce (Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH)

Abstract

B cell responses to membrane-presented antigens appear to be strongly favored over soluble antigens in vivo suggesting that vaccines that mimic membrane-presented antigens may be highly efficacious. We recently demonstrated that human B cell responses to membrane-associated but not to soluble antigens in vitro depended on the expression and activity of the plasma membrane mechanosensitive ion channel, Piezo1. Here, we provide evidence that the efficacy of the current human papillomavirus virus-like particle (HPV VLP) vaccines may be due in part to their inherent ability to mimic Piezo1-dependent membrane presentation of antigens to B cells. We compared HPV-specific human B cell responses to HPV VLPs versus soluble HPV pentameric capsomeres and showed that although both induced calcium responses, only HPV VLP-induced responses were blocked by Piezo1 inhibitors. The kinetics of internalization of HPV-VLP and capsomeres into HPV-specific B cells were similar and neither required Piezo1 function as shown by small interfering RNA (siRNA)-mediated knockdown of Piezo. However, trafficking of HPV-VLPs into intracellular major histocompatibility complex (MHC) class II, lysosomal associated membrane protein 1 (LAMP1) + antigen-processing compartments was Piezo1-dependent, whereas trafficking of capsomeres was not. In addition, a time course of intracellular trafficking suggested that colocalization of HPV-VLP with MHC classII was more stable over time as compared to capsomeres. Taken together these findings suggest that the ability of HPV-VLP vaccines to mimic Piezo1-dependent membrane antigen presentation may be exploited in the design of highly effective human vaccines.

Article Details

Volume / Issue Vol. 122, Issue 10
Published March 11, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (15)

C

Charles Torgbor

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

H

Haewon Sohn

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

B

Brian L. P. Dizon

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

E

Evan C. Mutic

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

R

Rachel George

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

K

Kihyuck Kwak

Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine

M

Munir Akkaya

Division of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, The Ohio State University

E

Esin Bayrali Ulker

Division of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, The Ohio State University

M

Maria Traver

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

J

Joseph Brzostowski

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH

D

Denise A. Galloway

Human Biology Division, Fred Hutchinson Cancer Research Center

C

Cynthia D. Thompson

Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH

N

Nicolas Çuburu

Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH

J

John T. Schiller

Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH

S

Susan K. Pierce

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH